BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bellizzi AM. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas. Histopathology 2020;76:251-64. [PMID: 31233624 DOI: 10.1111/his.13943] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Lanceta J, Toprak M, Rosca OC. Merkel cell carcinoma presenting as a malignant pleural effusion post-COVID-19 hospitalization: A case report and literature review. Diagn Cytopathol 2021. [PMID: 34609068 DOI: 10.1002/dc.24882] [Reference Citation Analysis]
2 Inzani F, Angelico G, Santoro A, Travaglino A, Insabato L, Raffone A, Arciuolo D, Scaglione G, D'Alessandris N, Valente M, Carlino A, Rindi G, Zannoni GF. SATB2 is expressed in neuroendocrine carcinoma of the uterine cervix. Virchows Arch 2022. [PMID: 35091815 DOI: 10.1007/s00428-021-03255-7] [Reference Citation Analysis]
3 Inoue H, Matsushima J, Kobayashi S, Sairenchi T, Hirata H, Chida M, Ota S, Ban S, Matsumura Y. Expression of nSATB2 in Neuroendocrine Carcinomas of the Lung: Frequent Immunopositivity of Large Cell Neuroendocrine Carcinoma with a Diagnostic Pitfall. Int J Surg Pathol 2021;:10668969211065757. [PMID: 34913369 DOI: 10.1177/10668969211065757] [Reference Citation Analysis]
4 Uccella S, Facco C, Chiaravalli AM, Pettenon F, La Rosa S, Turri-Zanoni M, Castelnuovo P, Cerati M, Sessa F. Transcription Factor Expression in Sinonasal Neuroendocrine Neoplasms and Olfactory Neuroblastoma (ONB): Hyams' Grades 1-3 ONBs Expand the Spectrum of SATB2 and GATA3-Positive Neoplasms. Endocr Pathol 2022. [PMID: 35522392 DOI: 10.1007/s12022-022-09715-3] [Reference Citation Analysis]
5 Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol 2020;96:8-33. [PMID: 31857137 DOI: 10.1016/j.humpath.2019.12.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
6 Mohanty SK, Tiwari A, Bhardwaj N, Chuang F, Kim E, Lugo H, Yuan X, Diffalha SA, Peralta-Venturina M, Balzer B, Dhall D. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours. J Clin Pathol 2021;74:582-8. [PMID: 32934105 DOI: 10.1136/jclinpath-2020-206645] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Bellizzi AM. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:185-208. [PMID: 32151355 DOI: 10.1016/j.soc.2019.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
8 Marjani S, Zirh S, Sever-Bahcekapili M, Cakir-Aktas C, Muftuoglu SF, Mut M. Doxycycline alleviates acute traumatic brain injury by suppressing neuroinflammation and apoptosis in a mouse model. J Neuroimmunol 2021;359:577672. [PMID: 34364104 DOI: 10.1016/j.jneuroim.2021.577672] [Reference Citation Analysis]
9 Mete O, Wenig BM. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms. Head Neck Pathol 2022. [PMID: 35312985 DOI: 10.1007/s12105-022-01435-8] [Reference Citation Analysis]
10 Lee W, Li X, Chandan VS. Hepatocellular carcinomas can be Special AT-rich sequence-binding protein 2 positive: an important diagnostic pitfall. Hum Pathol 2020;105:47-52. [PMID: 32946879 DOI: 10.1016/j.humpath.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Couvelard A, Cros J. An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs. Virchows Arch 2022. [PMID: 35278097 DOI: 10.1007/s00428-022-03306-7] [Reference Citation Analysis]
12 Asa SL, Arkun K, Tischler AS, Qamar A, Deng FM, Perez-Ordonez B, Weinreb I, Bishop JA, Wenig BM, Mete O. Middle Ear "Adenoma": a Neuroendocrine Tumor with Predominant L Cell Differentiation. Endocr Pathol 2021. [PMID: 34041698 DOI: 10.1007/s12022-021-09684-z] [Reference Citation Analysis]
13 Bellizzi AM, Montgomery EA, Hornick JL. American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies. Ann Diagn Pathol 2020;44:151419. [PMID: 31786484 DOI: 10.1016/j.anndiagpath.2019.151419] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Chen I, Zhang D, Velez M, Kovar S, Liao X. Poorly differentiated neuroendocrine carcinomas of the gastrointestinal tract: A single-institute study of 43 cases. Pathol Res Pract 2021;226:153614. [PMID: 34555651 DOI: 10.1016/j.prp.2021.153614] [Reference Citation Analysis]
15 Kenny B, Osmond A. CDX2 and SATB2 positivity in pilomatrix carcinoma: Avoiding an erroneous diagnosis of cutaneous metastasis of gastrointestinal origin. J Cutan Pathol 2021. [PMID: 34797586 DOI: 10.1111/cup.14172] [Reference Citation Analysis]
16 Yin F, Wu ZH, Lai JP. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(17): 1751-1767 [DOI: 10.3748/wjg.v28.i17.1751] [Reference Citation Analysis]
17 Vrana JA, Boland JM, Terra SBSP, Xie H, Jenkins SM, Mansfield AS, Molina JR, Cassivi SD, Roden AC. SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors. Am J Clin Pathol 2021:aqab038. [PMID: 33978159 DOI: 10.1093/ajcp/aqab038] [Reference Citation Analysis]
18 Yu S, Hornick JL, Gonzalez RS. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas. Virchows Arch 2021. [PMID: 33733343 DOI: 10.1007/s00428-021-03085-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Chua K, Virshup DM, Odono EG, Chang KTE, Tan NJH, Hue SS, Sim AYL, Lee VKM. YJ5 as an immunohistochemical marker of osteogenic lineage. Pathology 2021;53:229-38. [PMID: 33187685 DOI: 10.1016/j.pathol.2020.07.017] [Reference Citation Analysis]
20 Roy SK, Shrivastava A, Srivastav S, Shankar S, Srivastava RK. SATB2 is a novel biomarker and therapeutic target for cancer. J Cell Mol Med 2020;24:11064-9. [PMID: 32885593 DOI: 10.1111/jcmm.15755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 Neri G, Arpa G, Guerini C, Grillo F, Lenti MV, Giuffrida P, Furlan D, Sessa F, Quaquarini E, Viglio A, Ubezio C, Pasini A, Ferrero S, Sampietro G, Ardizzone S, Latella G, Mescoli C, Rugge M, Zingone F, Barresi V, Ciccocioppo R, Pedrazzoli P, Corazza GR, Luinetti O, Solcia E, Paulli M, Di Sabatino A, Vanoli A. Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic Pitfall. Cancers (Basel) 2020;12:E3441. [PMID: 33228145 DOI: 10.3390/cancers12113441] [Reference Citation Analysis]